Zealand Pharma A/S (ZLDPF)
PNK · Healthcare · Biotechnology
Closing price as of 2026-10-27 · Source: TEK2day Finance
Key Metrics
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Quarterly Financials (DKK)
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 49.6M | 68.9M | 34.0M | 4.5B |
| Gross Profit | 49.6M | 68.9M | 34.0M | 4.5B |
| Operating Income | (461.3M) | (356.5M) | (539.0M) | 3.9B |
| Net Income | (404.2M) | (379.1M) | (394.0M) | 3.9B |
| Diluted EPS | (DKK 5.75) | (DKK 5.58) | DKK 55.34 |
Annual Financials (DKK)
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 104.0M | 342.8M | 62.7M | 9.2B |
| Gross Profit | 104.0M | 323.6M | 54.8M | 9.2B |
| Operating Income | (816.6M) | (577.2M) | (1.3B) | 7.1B |
| Net Income | (1.2B) | (703.7M) | (1.1B) | 6.5B |
| Diluted EPS | (DKK 26.02) | (DKK 12.44) | (DKK 16.24) | DKK 90.22 |